Last updated: 2026-09-09 04:29:40. Prices reflect the latest closing data and will resume updating on the next trading day. Stock price data is sourced from Massive.
Monte Rosa Therapeutics, Inc. (GLUE) operates in the BIOLOGICAL PRODUCTS, (NO DIAGNOSTIC SUBSTANCES) sector and is listed on NASDAQ. The stock is currently priced at $14.27, with a market capitalization of $1.18B and a P/E ratio of --. Over the past 52 weeks, its price has ranged from $4.79 to $25.77. This page covers its latest market performance, valuation, price trends and company information.
$1.18B | |
$13.55 | |
$45.56 | |
$2.44 | |
$13.84 | |
1.00M | |
1.43M | |
-- | |
$25.77 | |
$4.79 | |
-- | |
-- |
Monte Rosa Therapeutics, Inc. (GLUE) last closed at $13.84 as of 2026-09-08 23:31:00, unchanged from the previous close of $13.84.
During the latest regular trading session, GLUE traded between $2.44 and $45.56, with a volume of 1.00M shares. The closing price was near the lower end and near the middle of its 52-week range.
Over the past seven days, Monte Rosa Therapeutics, Inc. (GLUE) moved from $14.32 to $14.27, representing a decline of 0.38% ($0.05).
The stock traded between $13.12 and $15.00 during the period. The latest price is near the middle of the 7-day range, indicating range-bound.
The average daily volume was 982.76 thousand shares, down versus the previous seven-day period, indicating lower trading activity.
Position in Range: 45.2%
GLUE is currently trading at $14.27, placing it 45.2% of the way from its 52-week low of $4.79 to its 52-week high of $25.77. This percentage reflects the stock's relative position within its 52-week trading range, not its valuation or future performance.
Monte Rosa Therapeutics Inc is a clinical-stage biotechnology company that specializes in developing molecular glue degraders (MGDs), a class of small molecule drugs that leverage the body's natural protein destruction mechanisms to selectively degrade therapeutically-relevant proteins. Utilizing the QuEEN platform, the company employ artificial intelligence and proprietary experimental tools to identify target proteins for degradation by MGDs. The company has three programs in clinical development: MRT-6160, a VAV1-directed MGD for immune-mediated diseases; MRT-8102, a NEK7-directed MGD for inflammatory diseases driven by IL-6, and the NLRP3 inflammasome; and MRT-2359, a GSPT1-directed MGD for metastatic castration resistant prostate cancer (mCRPC).
| Industry | BIOLOGICAL PRODUCTS, (NO DIAGNOSTIC SUBSTANCES) |
| Employees | 173 |
| Exchange | NASDAQ |
| Company Website |
Eligible investors can buy real shares of Monte Rosa Therapeutics, Inc. (GLUE) through MEXC RealStocks. Follow these three steps to open a RealStocks account, transfer USDT, and place a US stock order.